<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547143</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-H-72</org_study_id>
    <nct_id>NCT01547143</nct_id>
  </id_info>
  <brief_title>Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis</brief_title>
  <acronym>HELA2012</acronym>
  <official_title>Pilot Study of First-line Immunosuppressive Therapy Combined With Etoposide and Allogeneic Hematopoietic Cell Transplantation in Refractory/Reactivated Cases for Hemophagocytic Lymphohistiocytosis (HLH) in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators would like to propose a pilot study evaluating the efficacy of etoposide
      combined with immunosuppressive agents for adult secondary hemophagocytic lymphohistiocytosis
      (HLH), in order to prove out whether the modification of previous HLH-94 or HLH-2004 protocol
      for childhood patients can improve the outcome and decrease the toxicities. The results of
      this pilot study will be a base of a more-improved phase-2 protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of HLH in adult patients has not been determined yet. Actually, we adopted the
      treatment protocol HLH2004, which was developed for pediatric HLH patients. The HLH2004
      protocol, which is a potent and successful treatment for HLH, has shown some limitations in
      the treatment of adult HLH. First, the dose of etoposide is somewhat high for adult patients
      to tolerate. Second, the high incidence of opportunistic infection such as fungal, bacterial,
      and viral has threatened the patients. Third, more aggressive and intensive approach to adopt
      allogeneic hematopoietic cell transplantation will be needed earlier in adult patients. Based
      on these rationales, we developed a modified protocol based on HLH2004 to pit the treatment
      of adult HLH patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The PI resigned the institute, and the rest investigators at the institute decided to terminate
    the study.
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response rate</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reactivation-free survival rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reactivation-free survival rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related mortality rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>IST and/or alloHCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are newly diagnosed as HLH by HLH-2004 criteria, excluding those with HLH owing to malignancy or rheumatic disorder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IST and/or alloHCT</intervention_name>
    <description>1) Patients will be categorized by their initial serum ferritin level.
Mild ( ferritin&lt;3,000 μg/L): close observation
Moderate (ferritin: 3,000-10,000 μg/L):
Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)
continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.
Severe (ferritin&gt;10,000 μg/L):
initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)
continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.
2) AlloHCT for refractory or reactivated cases.</description>
    <arm_group_label>IST and/or alloHCT</arm_group_label>
    <other_name>Etoposide</other_name>
    <other_name>Cyclosporine: Cipol</other_name>
    <other_name>Dexamethasone</other_name>
    <other_name>IV gammaglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients whose clinical findings satisfy 5 or more criteria out of the following 8
             ones

               1. Fever ≥ 38.5 ℃ for ≥ 7 days

               2. Splenomegaly ≥ 3 FB below left subcostal margin

               3. Cytopenias affecting ≥ 2 of 3 lineages in PB Hb &lt; 9 g/L Platelet &lt; 100 x 109 /L
                  ANC &lt; 1.0 x 109 /L

               4. Hypertriglyceridemia and/or hypofibrinogenemia (fasting triglycerides ≥ 265
                  mg/dL, fibrinogen ≤ 1.5 g/L)

               5. Hemophagocytosis in BM or spleen or LN

               6. Low or absent NK-cell activity ( according to local laboratory reference)

               7. Serum-ferritin ≥ 500 mcg/L

               8. Soluble CD25(sIL-2 receptor) ≥ 2,400 U/ml

          -  18 years of age and over.

          -  All patients (or his/her family when the patient cannot sign the consent form because
             of his/her general conditions) give written informed consent according to guidelines
             at institution's committee on human research.

        Exclusion Criteria:

          -  HLH from malignancy (such as lymphoma, myeloma, leukemia, and other solid tumor)

          -  HLH from rheumatic disorder (such as SLE, AOSD, antiphospholipid antibody syndrome)

          -  Patients with psychiatric disorder or mental deficiency severe as to make compliance
             with the treatment unlike, and making informed consent impossible

          -  Nursing women, pregnant women, women of childbearing potential who do not want
             adequate contraception

          -  Male patient who reject the methods of avoiding pregnancy via methods such as
             abstinence, barrier method (condom etc).

          -  Patients with a diagnosis of prior malignancy unless disease-free for at least 5 years
             following therapy with curative intent (except curatively treated nonmelanoma skin
             cancer, in situ carcinoma, or cervical intraepithelial neoplasia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae-Young Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical center, University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Félix FH, Leal LK, Fontenele JB. Cloak and dagger: the case for adult onset still disease and hemophagocytic lymphohistiocytosis. Rheumatol Int. 2009 Jun;29(8):973-4. doi: 10.1007/s00296-008-0825-z. Epub 2008 Dec 30.</citation>
    <PMID>19115058</PMID>
  </reference>
  <reference>
    <citation>Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol. 2003 Sep;15(5):587-90. Review.</citation>
    <PMID>12960485</PMID>
  </reference>
  <reference>
    <citation>Chen JH, Fleming MD, Pinkus GS, Pinkus JL, Nichols KE, Mo JQ, Perez-Atayde AR. Pathology of the liver in familial hemophagocytic lymphohistiocytosis. Am J Surg Pathol. 2010 Jun;34(6):852-67. doi: 10.1097/PAS.0b013e3181dbbb17.</citation>
    <PMID>20442642</PMID>
  </reference>
  <reference>
    <citation>Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, Yamamoto K, Horiuchi H, Takada K, Ohshima K, Nakamura S, Kinukawa N, Oshimi K, Kawa K. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007 Jul;86(1):58-65.</citation>
    <PMID>17675268</PMID>
  </reference>
  <reference>
    <citation>Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31.</citation>
    <PMID>16937360</PMID>
  </reference>
  <reference>
    <citation>Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009:127-31. doi: 10.1182/asheducation-2009.1.127.</citation>
    <PMID>20008190</PMID>
  </reference>
  <reference>
    <citation>Gupta A, Tyrrell P, Valani R, Benseler S, Weitzman S, Abdelhaleem M. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008 Sep;51(3):402-4. doi: 10.1002/pbc.21564.</citation>
    <PMID>18523990</PMID>
  </reference>
  <reference>
    <citation>Chung HJ, Park CJ, Lim JH, Jang S, Chi HS, Im HJ, Seo JJ. Establishment of a reference interval for natural killer cell activity through flow cytometry and its clinical application in the diagnosis of hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 2010 Apr;32(2):239-47. doi: 10.1111/j.1751-553X.2009.01177.x. Epub 2009 Jul 15.</citation>
    <PMID>19614711</PMID>
  </reference>
  <reference>
    <citation>Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008 Jun;50(6):1227-35.</citation>
    <PMID>18085676</PMID>
  </reference>
  <reference>
    <citation>Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer. 2011 Jan;56(1):154-5. doi: 10.1002/pbc.22774.</citation>
    <PMID>20842751</PMID>
  </reference>
  <reference>
    <citation>Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol. 2011 Mar;163(3):271-83. doi: 10.1111/j.1365-2249.2010.04302.x. Review.</citation>
    <PMID>21303357</PMID>
  </reference>
  <reference>
    <citation>Horne A, Ramme KG, Rudd E, Zheng C, Wali Y, al-Lamki Z, Gürgey A, Yalman N, Nordenskjöld M, Henter JI. Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. Br J Haematol. 2008 Oct;143(1):75-83. doi: 10.1111/j.1365-2141.2008.07315.x. Epub 2008 Aug 15.</citation>
    <PMID>18710388</PMID>
  </reference>
  <reference>
    <citation>Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010 Jul 15;55(1):134-40. doi: 10.1002/pbc.22499.</citation>
    <PMID>20486178</PMID>
  </reference>
  <reference>
    <citation>Meeths M, Entesarian M, Al-Herz W, Chiang SC, Wood SM, Al-Ateeqi W, Almazan F, Boelens JJ, Hasle H, Ifversen M, Lund B, van den Berg JM, Gustafsson B, Hjelmqvist H, Nordenskjöld M, Bryceson YT, Henter JI. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood. 2010 Oct 14;116(15):2635-43. doi: 10.1182/blood-2010-05-282541. Epub 2010 Jun 17.</citation>
    <PMID>20558610</PMID>
  </reference>
  <reference>
    <citation>Yoon HS, Kim HJ, Yoo KH, Sung KW, Koo HH, Kang HJ, Shin HY, Ahn HS, Kim JY, Lim YT, Bae KW, Lee KO, Shin JS, Lee ST, Chung HS, Kim SH, Park CJ, Chi HS, Im HJ, Seo JJ. UNC13D is the predominant causative gene with recurrent splicing mutations in Korean patients with familial hemophagocytic lymphohistiocytosis. Haematologica. 2010 Apr;95(4):622-6. doi: 10.3324/haematol.2009.016949. Epub 2009 Dec 16.</citation>
    <PMID>20015888</PMID>
  </reference>
  <reference>
    <citation>Aricò M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001 Sep;114(4):761-9. Review.</citation>
    <PMID>11564062</PMID>
  </reference>
  <reference>
    <citation>Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, Lambert N, Ouachée-Chardin M, Chedeville G, Tamary H, Minard-Colin V, Vilmer E, Blanche S, Le Deist F, Fischer A, de Saint Basile G. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003 Nov 14;115(4):461-73.</citation>
    <PMID>14622600</PMID>
  </reference>
  <reference>
    <citation>Sieni E, Cetica V, Santoro A, Beutel K, Mastrodicasa E, Meeths M, Ciambotti B, Brugnolo F, zur Stadt U, Pende D, Moretta L, Griffiths GM, Henter JI, Janka G, Aricò M. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. J Med Genet. 2011 May;48(5):343-52. doi: 10.1136/jmg.2010.085456. Epub 2011 Jan 19.</citation>
    <PMID>21248318</PMID>
  </reference>
  <reference>
    <citation>Chang YH, Lee DS, Jo HS, Cho SI, Yoon HJ, Shin S, Yoon JH, Kim HY, Hong YJ, Hong SI, Cho HI. Tumor necrosis factor alpha promoter polymorphism associated with increased susceptibility to secondary hemophagocytic lymphohistiocytosis in the Korean population. Cytokine. 2006 Oct;36(1-2):45-50. Epub 2006 Dec 12.</citation>
    <PMID>17166738</PMID>
  </reference>
  <reference>
    <citation>Ishii E, Ueda I, Shirakawa R, Yamamoto K, Horiuchi H, Ohga S, Furuno K, Morimoto A, Imayoshi M, Ogata Y, Zaitsu M, Sako M, Koike K, Sakata A, Takada H, Hara T, Imashuku S, Sasazuki T, Yasukawa M. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood. 2005 May 1;105(9):3442-8. Epub 2005 Jan 4.</citation>
    <PMID>15632205</PMID>
  </reference>
  <reference>
    <citation>Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, Villanueva J, Risma KA, Wei Q, Klein PS, Filipovich AH. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011 Nov 24;118(22):5794-8. doi: 10.1182/blood-2011-07-370148. Epub 2011 Aug 31.</citation>
    <PMID>21881043</PMID>
  </reference>
  <reference>
    <citation>Sumegi J, Barnes MG, Nestheide SV, Molleran-Lee S, Villanueva J, Zhang K, Risma KA, Grom AA, Filipovich AH. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood. 2011 Apr 14;117(15):e151-60. doi: 10.1182/blood-2010-08-300046. Epub 2011 Feb 16.</citation>
    <PMID>21325597</PMID>
  </reference>
  <reference>
    <citation>Imashuku S, Tabata Y, Teramura T, Hibi S. Treatment strategies for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). Leuk Lymphoma. 2000 Sep;39(1-2):37-49. Review.</citation>
    <PMID>10975382</PMID>
  </reference>
  <reference>
    <citation>Imashuku S, Kuriyama K, Teramura T, Ishii E, Kinugawa N, Kato M, Sako M, Hibi S. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001 May 15;19(10):2665-73.</citation>
    <PMID>11352958</PMID>
  </reference>
  <reference>
    <citation>Henter JI, Samuelsson-Horne A, Aricò M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002 Oct 1;100(7):2367-73.</citation>
    <PMID>12239144</PMID>
  </reference>
  <reference>
    <citation>Ohga S, Kudo K, Ishii E, Honjo S, Morimoto A, Osugi Y, Sawada A, Inoue M, Tabuchi K, Suzuki N, Ishida Y, Imashuku S, Kato S, Hara T. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer. 2010 Feb;54(2):299-306. doi: 10.1002/pbc.22310.</citation>
    <PMID>19827139</PMID>
  </reference>
  <reference>
    <citation>Cooper N, Rao K, Gilmour K, Hadad L, Adams S, Cale C, Davies G, Webb D, Veys P, Amrolia P. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood. 2006 Feb 1;107(3):1233-6. Epub 2005 Oct 11.</citation>
    <PMID>16219800</PMID>
  </reference>
  <reference>
    <citation>Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31. doi: 10.1182/blood-2010-04-282392. Epub 2010 Sep 20.</citation>
    <PMID>20855862</PMID>
  </reference>
  <reference>
    <citation>Dürken M, Horstmann M, Bieling P, Erttmann R, Kabisch H, Löliger C, Schneider EM, Hellwege HH, Krüger W, Kröger N, Zander AR, Janka GE. Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients. Br J Haematol. 1999 Sep;106(4):1052-8.</citation>
    <PMID>10520013</PMID>
  </reference>
  <reference>
    <citation>Jabado N, de Graeff-Meeder ER, Cavazzana-Calvo M, Haddad E, Le Deist F, Benkerrou M, Dufourcq R, Caillat S, Blanche S, Fischer A. Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors. Blood. 1997 Dec 15;90(12):4743-8.</citation>
    <PMID>9389690</PMID>
  </reference>
  <reference>
    <citation>Horne A, Janka G, Maarten Egeler R, Gadner H, Imashuku S, Ladisch S, Locatelli F, Montgomery SM, Webb D, Winiarski J, Filipovich AH, Henter JI; Histiocyte Society. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol. 2005 Jun;129(5):622-30.</citation>
    <PMID>15916685</PMID>
  </reference>
  <reference>
    <citation>Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 1983 Jun-Jul;140(3):221-30. Review.</citation>
    <PMID>6354720</PMID>
  </reference>
  <reference>
    <citation>Cesaro S, Locatelli F, Lanino E, Porta F, Di Maio L, Messina C, Prete A, Ripaldi M, Maximova N, Giorgiani G, Rondelli R, Aricò M, Fagioli F. Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica. 2008 Nov;93(11):1694-701. doi: 10.3324/haematol.13142. Epub 2008 Sep 2.</citation>
    <PMID>18768529</PMID>
  </reference>
  <reference>
    <citation>Filipovich AH. Hemophagocytic lymphohistiocytosis and related disorders. Curr Opin Allergy Clin Immunol. 2006 Dec;6(6):410-5. Review.</citation>
    <PMID>17088644</PMID>
  </reference>
  <reference>
    <citation>Haddad E, Sulis ML, Jabado N, Blanche S, Fischer A, Tardieu M. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood. 1997 Feb 1;89(3):794-800.</citation>
    <PMID>9028310</PMID>
  </reference>
  <reference>
    <citation>Jordan MB, Filipovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant. 2008 Oct;42(7):433-7. doi: 10.1038/bmt.2008.232. Epub 2008 Aug 4. Review.</citation>
    <PMID>18679369</PMID>
  </reference>
  <reference>
    <citation>Imashuku S, Kuriyama K, Sakai R, Nakao Y, Masuda S, Yasuda N, Kawano F, Yakushijin K, Miyagawa A, Nakao T, Teramura T, Tabata Y, Morimoto A, Hibi S. Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center. Med Pediatr Oncol. 2003 Aug;41(2):103-9.</citation>
    <PMID>12825212</PMID>
  </reference>
  <reference>
    <citation>Tseng YT, Sheng WH, Lin BH, Lin CW, Wang JT, Chen YC, Chang SC. Causes, clinical symptoms, and outcomes of infectious diseases associated with hemophagocytic lymphohistiocytosis in Taiwanese adults. J Microbiol Immunol Infect. 2011 Jun;44(3):191-7. doi: 10.1016/j.jmii.2011.01.027. Epub 2011 Jan 20.</citation>
    <PMID>21524613</PMID>
  </reference>
  <reference>
    <citation>Park HS, Kim DY, Lee JH, Lee JH, Kim SD, Park YH, Lee JS, Kim BY, Jeon M, Kang YA, Lee YS, Seol M, Lee YJ, Lim YS, Jang S, Park CJ, Chi HS, Lee KH. Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis from causes other than lymphoma: an analysis of treatment outcome and prognostic factors. Ann Hematol. 2012 Jun;91(6):897-904. doi: 10.1007/s00277-011-1380-3. Epub 2011 Dec 8.</citation>
    <PMID>22147006</PMID>
  </reference>
  <reference>
    <citation>Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. J Pediatr Hematol Oncol. 2011 Jan;33(1):35-9. doi: 10.1097/MPH.0b013e3181f84a52.</citation>
    <PMID>21088619</PMID>
  </reference>
  <reference>
    <citation>Shin HJ, Chung JS, Lee JJ, Sohn SK, Choi YJ, Kim YK, Yang DH, Kim HJ, Kim JG, Joo YD, Lee WS, Sohn CH, Lee EY, Cho GJ. Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci. 2008 Jun;23(3):439-44. doi: 10.3346/jkms.2008.23.3.439.</citation>
    <PMID>18583880</PMID>
  </reference>
  <reference>
    <citation>Jin YK, Xie ZD, Yang S, Lu G, Shen KL. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: a retrospective study of 78 pediatric cases in mainland of China. Chin Med J (Engl). 2010 Jun;123(11):1426-30.</citation>
    <PMID>20819601</PMID>
  </reference>
  <reference>
    <citation>Raschke RA, Garcia-Orr R. Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults. Chest. 2011 Oct;140(4):933-938. doi: 10.1378/chest.11-0619. Epub 2011 Jul 7. Review.</citation>
    <PMID>21737492</PMID>
  </reference>
  <reference>
    <citation>Belyea B, Hinson A, Moran C, Hwang E, Heath J, Barfield R. Spontaneous resolution of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2010 Oct;55(4):754-6. doi: 10.1002/pbc.22618.</citation>
    <PMID>20806367</PMID>
  </reference>
  <reference>
    <citation>Gupta AA, Tyrrell P, Valani R, Benseler S, Abdelhaleem M, Weitzman S. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution. J Pediatr Hematol Oncol. 2009 Feb;31(2):81-4. doi: 10.1097/MPH.0b013e3181923cb4.</citation>
    <PMID>19194188</PMID>
  </reference>
  <reference>
    <citation>Imashuku S, Hibi S, Sako M, Ishida Y, Mugishima H, Chen J, Tsunematsu Y. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood. 1995 Dec 15;86(12):4706-7.</citation>
    <PMID>8541568</PMID>
  </reference>
  <reference>
    <citation>Mahlaoui N, Ouachée-Chardin M, de Saint Basile G, Neven B, Picard C, Blanche S, Fischer A. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007 Sep;120(3):e622-8. Epub 2007 Aug 14.</citation>
    <PMID>17698967</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Dae-Young Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Secondary hemophagocytic lymphohistiocytosis of adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

